-
Tytuł:
-
[Experience of using interferon Β-1a biosimilans (cinnovex and genfaxon-44) in the Moscow Multiple Sclerosis Center].
-
Autorzy:
-
Borets OG; Moscow Multiple Sclerosis Center of the City Hospital #24, Moscow.
Davydovskaya MV; Moscow Multiple Sclerosis Center of the City Hospital #24, Moscow; Pirogov Russian National Research Medical University, Moscow.
Demina TL; Moscow Multiple Sclerosis Center of the City Hospital #24, Moscow; Pirogov Russian National Research Medical University, Moscow.
Lashch NY; Moscow Multiple Sclerosis Center of the City Hospital #24, Moscow; Pirogov Russian National Research Medical University, Moscow.
Popova NF; Moscow Multiple Sclerosis Center of the City Hospital #24, Moscow; Pirogov Russian National Research Medical University, Moscow.
Popova EV; Moscow Multiple Sclerosis Center of the City Hospital #24, Moscow; Pirogov Russian National Research Medical University, Moscow.
Khachanova NV; Moscow Multiple Sclerosis Center of the City Hospital #24, Moscow; Pirogov Russian National Research Medical University, Moscow.
Khasayeva MV; Moscow Multiple Sclerosis Center of the City Hospital #24, Moscow; Pirogov Russian National Research Medical University, Moscow.
Shchur SG; Moscow Multiple Sclerosis Center of the City Hospital #24, Moscow.
Boyko AN; Moscow Multiple Sclerosis Center of the City Hospital #24, Moscow; Pirogov Russian National Research Medical University, Moscow.
-
Transliterated Title:
-
Opyt primeneniia bioanalogov Β-interferona-1a - sinnoveksa i genfaksona-44 v Moskovskom gorodskom tsentre rasseiannogo skleroza.
-
Źródło:
-
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2015; Vol. 115 (2 Pt 2), pp. 51-56.
-
Typ publikacji:
-
English Abstract; Journal Article
-
Język:
-
Russian
-
Imprint Name(s):
-
Publication: <1995->: Moskva : Media Sfera
Original Publication: Moskva : "Meditsina",
-
Contributed Indexing:
-
Local Abstract: [Publisher, Russian] Цель исследования - изучение эффективности и переносимости воспроизведенных препаратов (биоаналогов β-интерферон-1а) - синновекса для внутримышечного введения и генфаксона-44 для подкожного введения при рассеянном склерозе (PC). Материал и методы. Лечились в течение года синновексом 100 больных PC, генфаксоном - 104 пациента. Их состояние оценивалось клинически, по ряду шкал и данным МРТ. Результаты и заключение. В процессе лечения был отмечен высокий процент случаев отмены терапии в связи с клинической неэффективностью и непереносимостью изучавшихся препаратов. Положительный эффект в отношении стабилизации течения PC был отмечен только у больных, которые ранее не лечились препаратами, изменяющими течение рассеянного склероза (ПИТРС). Считают, что для окончательного решения вопроса о соответствии оригинального и 'воспроизведенного' лекарственного средства необходимо проведение двойных слепых исследований.
-
Entry Date(s):
-
Date Created: 20150618 Latest Revision: 20191120
-
Update Code:
-
20240104
-
DOI:
-
10.17116/jnevro20151152251-56
-
PMID:
-
26081337
-
Objective: To study the efficacy and tolerability of generics (interferon beta-1a biosimilans) cinnovex for intramascular introduction and genfaxon-44 for subcutaneous injections in multiple sclerosis (MS).
Material and Methods: One hundred patients were treated with cinnovex and 104 patients were treated with genfaxon-44 during one year. Patient's status was assessed using clinical approach, psychometric scales and MRI.
Results and Conclusion: The high percentage of withdrawal of treatment due to the lack of clinical effect and intolerance to the drugs was identified during the treatment. Positive effect with respect to stabilization of MS course was found only in patients who earlier did not receive disease-modifying drugs. Double-blind studies are needed to resolve the question of the adequacy of brand-name drugs and generics.
